SCR-LIP-000390 · Claim · machine-readable JSON →

In a retrospective study of lipedema patients undergoing multistage lymph-sparing liposuction, BMI decreased by a median of 2.7 kg/m2 and patients with BMI ≤35 had greater symptom (VAS composite 51.6% vs 25.3%) and conservative-therapy-need reduction than those with BMI >35, but liposuction volume did not correlate with symptom or treatment-need reduction; the study did not evaluate bariatric surgery or substantial weight loss as the intervention.

Claim at a glance

Structured evidence, machine-compiled — not a verdict.

Auto-compiled by the Layer 1 surveillance loop; not yet human-reviewed. anthropic/claude-opus-4.8 · 2026-05-31

Evidence over time

Disease progression and comorbidities in lipedema patients: A 10‐year retrospective analysis — Ghods et al. (2022) ✓ verified — refining · case series · 2022 · reading confidence: high
The article studies liposuction, not bariatric surgery or weight loss as the intervention; it indirectly bears on the question by showing lower BMI (≤35) predicts better outcomes and a small BMI decrease post-op, but does not directly test

Populationlipedema patients undergoing multistage lymph-sparing liposuction

Conditionlipedema

ExposureBMI ≤35 at time of liposuction

ComparatorBMI >35 at time of liposuction

OutcomeVAS composite symptom reduction and conservative therapy need

Scopeauto-ingested from Layer 1 surveillance

Auto-ingested single source; not yet human-reviewed.